Atossa Therapeutics Announces Publication of Novel (Z)-Endoxifen-Related Compounds Demonstrating Potent Anti-Cancer Activity in ER-Positive Breast Cancer

Atossa Therapeutics announced the publication of a peer-reviewed preclinical study in npj Breast Cancer evaluating five novel chemical entities related to its lead asset (Z)-endoxifen. The study demonstrated potent anti-estrogenic and anti-cancer activity across multiple estrogen receptor-positive breast cancer models, including those harboring treatment-resistant ESR1 mutations.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.